arrow
S

Sivasish Sindiri

national institutes of health
H指数:30
被引数:4,616

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

NOTCH1 reverses immune suppression in small cell lung cancer through reactivation of STING

NOTCH1通过重新激活STING逆转小细胞肺癌中的免疫抑制

2025-09-162
OA
Adoptive transfer of personalized neoantigen-reactive TCR-transduced T cells in metastatic colorectal cancer: phase 2 trial interim results

转移性结直肠癌中个性化新抗原反应性TCR转导T细胞的过继转移: 2期试验中期结果

2024-07-114
OA
Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes

肿瘤浸润淋巴细胞的新抗原特异性刺激可实现有效的TCR隔离和扩增,同时保留干细胞样记忆表型

2024-05-302
OAAI
IMPACT restrains immuno-metabolic GCN1 signaling to govern pancreatic cancer metastasis
2024-01-160
PRE
Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers

来自转移性人类癌症的抗肿瘤新抗原反应性T细胞的分子特征

Science
IF45.8
2022-01-010
OA
Immuno-transcriptomic profiling of extracranial pediatric solid malignancies
2021-11-0135
OAAI
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer

EGFR突变型肺癌中奥希替尼获得性耐药机制的克隆进化和异质性

2020-04-01109
OAAI
An integrated genomic, epigenetic, proteomic, and single cell analysis of pediatric B cell acute lymphoblastic leukemia to elucidate resistance mechanisms to CD19 CAR T cell therapy
2019-07-010
PRE
APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors
2019-03-0182
OAAI
Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas
2019-02-0573
OAAI
MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma
2018-07-0499
OAAI
Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma
2018-02-2841
OAAI